XmAb819-01

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jul 16, 2025 → Oct 27, 2026

Cited window

Nov 20, 2025 → Oct 27, 2026

Retrieved

Oct 29, 2026

Title

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Registry

NCT05433142

Study IDs

XmAb819-01

Sponsor

Xencor, Inc.

Design

Phase 1 · Interventional, sequential

Status

Recruiting

Enrollment

307 estimated

Start

2022-06-13 actual

Primary completion

2027-02 estimated

Primary endpoint

Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on treatment activity after prior therapy and continued treatment among responders in heavily pretreated clear cell renal cell carcinoma.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational reports, analyst assessments and reposts must not be counted as independent clinician endorsements.
• –Some discussions were only partly assessed, and 52 additional sources without an explicit trial-name mention were not read. Relevant discussion using unnamed references or different transcription variants may be missing.
• –Several posts discuss XmAb819 or its phase 1 ccRCC setting without identifying NCT05433142. Their observations remain attributed contextual reports rather than independently identifier-confirmed results.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –No full protocol, results publication for NCT05433142 or XmAb819 regulatory label was available in the sources reviewed. The reported efficacy, toxicity and development assertions cannot be reconciled against those documents here.
• –Different cohort scopes, adverse-event categories and cutoff descriptions prevent combining the reported figures into one efficacy or safety estimate. Treatment persistence does not establish mature duration of response.
• –The a speaker post is dated November 2025, whereas the other cited commentary is dated October 2026. Post dates do not establish readout dates, longitudinal changes of view or direct disagreement.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "XmAb819-01" (NCT05433142), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "xmab819-01-05433142". If you cannot make requests, read https://www.erudio.com/reports/xmab819-01-nct05433142.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05433142", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05433142 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/xmab819-01-nct05433142.json
curl https://www.erudio.com/reports/xmab819-01-nct05433142.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "xmab819-01-05433142" })